Ildong Pharmaceutical said April 14 it signed an additional agreement with its Indonesian partner, Kalbe Pharma, to expand the supply territory for its drug DropTop as it broadens its presence in Southeast Asia.
DropTop is a combination therapy for dyslipidemia that pairs rosuvastatin, a statin that inhibits cholesterol synthesis, with ezetimibe, which reduces cholesterol absorption.
Ildong said it signed a contract with Kalbe International, a distribution affiliate of Kalbe Pharma, to expand DropTop supply to three ASEAN countries. With the deal, Ildong will have a cooperation framework with the Kalbe Group in a total of eight Southeast Asian countries, including Indonesia, its existing supply market.
Ildong signed a partnership agreement with Kalbe Pharma in 2020 and has continued exports since 2023 after completing approval and launch procedures.
The product is sold locally under the brand name “Rozet.” Ildong said it has posted average annual growth of about 130% over the past three years since launch and ranks No. 1 by market share in Indonesia’s dyslipidemia combination-drug market.
Ildong said it plans to pursue product approvals and launches in the newly covered countries in stages, and to accelerate market entry with localized marketing and distribution strategies.
“Through this agreement, DropTop can enter most ASEAN member states,” a company official said. “Working with the Kalbe Group, we will continue to expand our market reach and product lineup.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.